Pursuant to Regulation 47(3) of SEBI (LODR) Regulation, 2015 Please find the enclosed herewith the News paper Clipping of our Published Results in FRESS PRESS JOURNAL and NAV SHAKTI on ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Colinz Laboratories Ltd has submitted to BSE the newspaper clippings of its unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26), published in Free Press Journal and Navshakti on August 1, 2025, as required under SEBI LODR Regulation 47(3). Revenue from operations for the quarter stood at Rs. 164.11 lacs, down from Rs. 181.39 lacs in Q1 FY25, a year-on-year decline of about 9.5%. Net profit after tax fell to Rs. 11.92 lacs from Rs. 13.72 lacs, a drop of roughly 13%. Basic and diluted EPS for the quarter slipped to Rs. 0.47 from Rs. 0.54 year-on-year. The board approved the results at its meeting on July 31, 2025, and a limited review was carried out by the statutory auditors. For reference, the full-year FY25 (audited) showed revenue of Rs. 682.56 lacs and net profit after tax of Rs. 49.66 lacs, translating to an EPS of Rs. 1.97.
Both top line and bottom line have shrunk compared to the same quarter last year, which is mildly negative for shareholders; however, the company remains profitable and the prior full-year EPS of Rs. 1.97 indicates a stable earnings base for this small-cap pharma stock.